
Opinion|Videos|October 28, 2024
Dual Maintenance With BiTE and PD-L1 Inhibitors
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy for patients with ES-SCLC, highlighting that statistically significant trial end points, such as improved PFS and OS, could encourage community oncologists to adopt this dual maintenance approach.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What PFS and OS end points would you typically expect from second- or third-line therapy in your previously treated patients with relapsed/refractory SCLC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















